Dr George D. Yancopoulos, Regeneron’s chief scientific officer, said: “We are honoured that the Galien Foundation has recognised Inmazeb […] Our ability to rapidly respond to Ebola was based ...

Inmazeb Arcalyst, and Zaltrap. The biotech company's shares have lagged behind the broader market over the past 52 weeks. Regeneron has declined 26.5% over this time frame, while the broader S&P ...

Regeneron Pharmaceuticals ... Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process ...

In January, Regeneron announced preliminary data showing the medicine ... Stahl and his team had come up with the first-ever FDA-approved treatment for the illness. Inmazeb consists of three ...

Tarrytown, New York-based Regeneron Pharmaceuticals ... Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. Companies worth $10 billion or more are generally described as “large-cap stocks ...

Who Are the Key Players in the Inmazeb Market? .A leading company in the Inmazeb market is Regeneron Pharmaceuticals Inc. .The market remains highly competitive, with companies focusing on ...

Regeneron Pharmaceuticals ... In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including ...